OPTOCIRCUI

Opto Circuits (India) Limited has submitted to the Exchange a copy of Utilisation of Public Issue Proceeds. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Opto Circuits (India) Limited has informed the Exchange that M/s Eurocor Gmbh an opto Circuits (India) Limited company received CE mark approval of its new Polymer-free, Taxcor i.Paclitaxel -eluting coronary stent system. This innovative while Polymer-free, drug-eluting stent technology eliminates any polymer-related, late adverse effect potential for the patient, like subacute thrombosis. Blood clot formation and late thrombotic events are commonly known complications, after implantation of drug-eluting coronary stent systems, which have a permanent polymeric drug carrier, coated on the stent

Opto Circuits (India) Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on June 13, 2006 has recommended one Equity Bonus Shares for every one fully paid Equity Shares, subject to the approval of the shareholders in the General Meeting.

Opto Circuits (India) Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on June 13, 2006 has recommended 40% dividend for the year 2005-2006.

Citibank, N.A has informed the Exchange that Citigroup Global Mkts (Mauritius) Pvt Ltd has acquired 9,553 shares aggregating to 0.031% of the total paid up capital of Opto Circuits Limited on April 24, 2006. The mode of acquisition is through Secondary Market Purchase and the shareholding of Citigroup Global Mkts (Mauritius) Pvt Ltd after the said acquisition is 15,46,424 shares aggregating to 5.02% of the total paid up capital of Opto Circuits Limited.

Opto Circuits (India) Limited has informed the Exchange that Citigroup Global Mkts (Mauritius) Pvt Ltd has acquired 9,553 shares aggregating to 0.031% of the total paid up capital of Opto Circuits Limited on April 24, 2006. The mode of acquisition is through Secondary Market Purchase and the shareholding of Citigroup Global Mkts (Mauritius) Pvt Ltd after the said acquisition is 15,46,424 shares aggregating to 5.02% of the total paid up capital of Opto Circuits Limited.

Opto Circuits (India) Limited has informed the Exchange that Eurocor GmbH the Company's wholly owned subsidiary has received the CE Mark Approval of its Amadeus Supercross coronary dilation catheters used in vascular coronary perfusion and also for their new range of PTCA guide wires branded E-WIRE for interventional use. In March 2006, the company got the CE certification for their Drug Eluting Stent TAXCOR. With these new regulatory CE certificates all the products of Eurocor are now CE Certified, allowing the Company to market all its products in the Eurpoean Union as well as in Fareast, Mi

Opto Circuits (India) Limited has informed the Exchange that M/s Eurocor Gmbh an Opto Circuits (India) Limited company recently participated in PCR (Paris Course on Revascularization) in Paris to show case its Stent Products. It was the largest convention for the interventional cardiologist outside United States. M/s Eurocor Gmbh has signed with a large Distributor in Brazil to cover Latin American markets for marketing its blockbuster drug eluting stent "TAXCOR". The deal is worth over Rs. 135.00 million. The Company will also be participating in the largest South American Interventional Card

Opto Circuits (India) Limited has informed the Exchange that according to the beneficiary position (benpos) received for the week ended May 05, 2006 from the company's Registrars and Transfer Agents M/s Karvy Computershare Pvt. Ltd., the holdings of M/s Citigroup Global Markets Mauritius Private Limited FII has gone upto 1681235 equity shares representing 5.46% of equity of the Company.

Opto Circuits (India) Limited has informed the Exchange that M/s Eurocor, an opto Circuits (India) Limited company signed a distribution agreement signed with, M/s Fumedica AG, a well established German medical device sales distributor. Fumedica will distribute Eurocar's entire range of coronary stent systems & balloon dilation catheters for the German & Swiss markets. This is the first major agreement Signed by EuroCor, after it has been acquired by opto Circuits (I) Ltd & is expected to generate revenues of approximately Rs.270 million during the Current year.

Opto Circuits (India) Limited has submitted to the Exchange the resolution passed by the Board of Directors of the Company through circulation effected on April 07, 2006 for approval on Underwriting Agreement. A copy of resolution shall be available on the NSE website (http://www.nseindia.com) under: Corporates > LateLatest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Opto Circuits (India) Limited has informed the Exchange that the Board of Directors in its meeting held on March 29, 2006 has fixed a price band of Rs.240/- to Rs.270/- (Rs.240/- being lower end of the price band and Rs.270/- being the upper end of the price band). A copy of the Board Resolution passed in this regard shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Opto Circuits (India) Limited has informed the Exchange that with reference to the approval of Red Herring Prospectus the Board of Directors at their Board Meeting held on March 20, 2006 approved the Red Herring Prospectus.

Opto Circuits (India) Limited has informed the Exchange that the Red Herring Prospectus ("DRHP") relating to the further public offering of 40,00,000 equity shares of Rs.10/- each-reserved categary, SEBI has approved the said DRHP with certain comments. In DRHP, the company has made a reservation of 4,00,000 shares of Rs.10/- each for employees and 4,00,000 shares of Rs.10/- each for existing retail investors. In this regard, the Company hereby informs that for the purpose of determining existing retail shareholders, the Company has decided upon March 10, 2006 as the specified date. All natura

Opto Circuits (India) Limited has informed the Exchange that Eurocor GmbH the Company's wholly owned subsidiary has received the CE Mark Approval of its TAXCOR Paclitaxel-eluting Coronary Stent System. This regulatory certification allows Eurocor to begin marketing the drug eluting stents in 25 Countries of the European Union as well as in Middle East Latin America and Asia. This product is based on the Mega flexibility platform technology which ensures lowest Stent friction to the arterial wall in particular after drug elution is done.

Opto Circuits (India) Limited has informed the Exchange that the Company has acquired M/s Altron Industries (Pvt) Limited, Bangalore for approximate consideration of Rs.52.00 lacs to enhance the company's manufacturing capacity.

Opto Circuits (India) Limited has informed the Exchange that the Company has completed the acquisition process of Euro Cor Gmbh a Medical Equipment Company in Germany. The Company manufactures Cardiac Stents of various types including Drug Eluting Stents used in Critical Cardiac Care.

Opto Circuits (India) Limited has informed the Exchange that the BODs at their meeting held on January 16, 2006 approved the Draft Red Herring Prospectus for filing with SEBI and other Regulatory Authorities.

Opto Circuits (India) Limited has informed the Exchange that at the Board Meeting held on December 31, 2005, appointment of following Directors as independent Directors have been accepted and recorded. (1) Mr. Balasubramaniam V - Independent Director; (2) Mr. Rajkumar Raisinghani - Independent Director and (3) Dr. Anvay Mulay - Independent Director. Mr. Mahesh Patel has resigned as Director with effect from December 31, 2005.

Opto Circuits (India) Limited has informed the Exchange that the Company has acquired Eurocor GmbH, a German Company, for a consideration of approximately Rs. 60/- crores. Eurocor GmbH manufacturers Cardiac & Peripheral Stents of various types including Drug Eluting Coronary Stents used in Critical Cardiac Care.

Opto Circuits (India) Limited has informed the Exchange that the BODs at its meeting held on November 24, 2005 considered and approved the offering of equity shares to the Public up to Rs.100 crores by the book building route. The funds will be deployed for acquisitions and expansion.

Opto Circuits (India) Limited has informed the Exchange that the following items were approved by the Shareholders of the Company at the EGM held on November 15, 2005. (1) Increase in the Authorised Capital from existing Rs.35 crores to Rs.50 crores and Alteration of Memorandum of Association. (2) To raise funds upto USD 70 Million. (3) Increase the Borrowing powers of the Company to Rs.500.00 crores. (4) Increase the FII Limit to 40% of the Issued Equity Capital of the Company.

Opto Circuits (India) Limited has submitted to the Exchange a copy of the Notice of EGM of the sharsholders of the Company to be held on November 15, 2005.The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Opto Circuits (India) Limited has informed the Exchange that the Company has signed a letter of intent to acquire a Medical Equipment Company in Europe. The Company manufactures Cardiac Stents of various types including Drug Eluting coronary Stents used in Critical Cardiac Care.The acquisition is estimated at Rs.60 crores and is subject to Financial and legal duediligence.

Opto Circuits (India) Limited has informed the Exchange that Mediaid Inc a 100% subsidiary of Company has been awarded a new distribution and pricing agreement by Defense Personnel Support Centre (DPSC) in Philadelphia, USA for its extensive line of FDA approved products like Spo2 Sensors, and Patient Monitoring Devices. The DPSC administers the Department of Defense's program, which are dedicated to the support of America's Military and any fully federally funded medical facility. The Defense Personnel Support Centre includes :- a) Department of Defense- i) DoD Medical Treatment Facilities (M

Opto Circuits (India) Limited has informed the Exchange that the Company has been accorded TWO STAR EXPORT TRADING HOUSE STATUS in accordance with the Provisions of EXIM Policy, from ministry of Commerce and Industry, Government of India.

Opto Circuits (India) Limited has informed the Exchange that the Board at its meeting held on September 16, 2005, has decided to raise up to USD 70 million by way of Private placement / Preferential allotment / Rights Issue / Second Public Offering of Equity Shares, or by way of Debts to support the R & D activities, future growth of the company and to enter into strategic joint ventures / acquisition of business in India or abroad. It was further decided to call an EGM of the Equity shareholders.

Opto Circuits (India) Limited has informed the Exchange that the Company has fixed August 17, 2005 as record date for allotting Bonus Shares to the Equity Share holders.

Opto Circuits (India) Limited has submitted to the Exchange a copy of the resolution passed by the shareholders at their meeting held on July 21, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Opto Circuits (India) Limited has informed the Exchange that the following items were approved by the shareholders of the Company at their AGM held on July 21, 2005 :- 1) Payment of dividend @ 35% for the year ended March 31, 2005. 2) Issue of Bonus shares-5 bonus Shares for every 10 fully paid shares. 3) Sub-division of face value of Equity shares from Rs. 10/- to Rs. 5/- each.4)Alteration of Articles of Association. 5) Employee Stock Option Plan. 6) Re-appointment of Mr. Vinod Ramnani as Managing Director. 7) Re-appointment of Mrs. Usha Ramnani as Executive Director.

Opto Circuits (India) Limited has informed the Exchange that the Register of Members and Share Transfer Books will be closed from July 12, 2005 to July 15, 2005 (both days inclusive) for the purpose of payment of dividend of 35%. The AGM of the members of the company will be held on July 21, 2005.

Opto Circuits (India) Limited has informed the Exchange that the Company has received first contract from a US Company for its SPO2 sensors which got FDA approval recently. The approximate value of the contract is Rs. 130.00 million.

Opto Circuits (India) Limited has informed the Exchange that the following items were approved by the Shareholders of the Company at the EGM held on May 10, 2005: 1) Increase in the Authorised Capital from existing Rs. 20 crores to Rs. 35 crores and Alteration of Memorandum of Association. 2) Issue of GDR and/or any other instruments aggregating to USD 20 Million with a Green Shoe option of USD 5 Million.

Opto Circuits (India) Limited has informed the Exchange that the BOD's at its meeting held on May 09, 2005, have recommended payment of dividend of 35% for the year 2004-05, and also issue of Five Bonus Shares for every Ten fully paid up shares, subject to the approval of shareholders in the AGM.

Opto Circuits (India) Limited has informed the Exchange that the EGM to be held on May 05, 2005 has been rescheduled to May 10, 2005.

Opto Circuits (India) Limited has informed the Exchange that the Board has decided to go for a GDR issue of USD 20Mn with a Green Shoe option of USD 5Mn. The Company proposes to raise funds to fund their expansions and for acquisition of Businesses. A portion of the issue will be used for setting up a world-class R & D facility in Bangalore. The GDR issue is subject to approval of the shareholders. The Board has recommended for calling the EGM of the company on May 5, 2005.

Opto Circuits (India) Limited has informed the Exchange that the company is establishing offices in the following places to market its SPO2 Products, which are already approved by the FDA, United States of America: 1)Dubai-UAE, 2)Chile-South America, 3)Dusseldorf-Germany.

Opto Circuits (India) Limited has informed the Exchange that the BoD's at their meeting held on January 19, 2005, have approved the splitting the existing face value of equity shares from Rs.10/- to Rs.5/- per share, subject to the approval of the shareholders.

Opto Circuits (India) Limited has informed the Exchange that the Company has fixed October 21, 2004 as the Record Date for allotting Bonus Shares to the Equity Share holders.

Opto Circuits (India) Limited has informed the Exchange that the following items were approved by the members of the company at its AGM held on September 30, 2004. 1. Payment of dividend @ 30% for the year ended March 31, 2004. 2. Issue of Bonus Shares-3 bonus shares for every 10 fully paid shares.

Opto Circuits (India) Limited has informed the Exchange that the company's wholly owned subsidiary Mediaid Inc. USA has received 510 (k) approval from the Food and Drug Administration (FDA) for its products, paving the way to market Mediaid SpO2 Sensors in the United States of America.

Clarification of News : The press had reports on November 07, 2003 that Opto Circuits (India) Limited has bagged a $4 million order for supply of blood cholesterol monitoring devices from Lifestream Inc, USA. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Opto Circuits (India) Limited has vide its letter inter-alia stated, "We would like to confirm the receipt of the order from Lifestream Technologies Inc. USA